Penicillamine Capsule
Product Images NDC 0591-4171

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Penicillamine (NDC 0591-4171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Penicillamine Capsules 210976 1)

FDA Label Image

Process (Penicillamine Capsules 210976 2)

This text describes the chemical abbreviations and formulas for cystine, cysteine (deprotonated), penicillamine, deprotonated penicillamine sulfhydryl, and penicillamine-cysteine mixed disulfide. It includes chemical equations showing the reactions between these compounds.*

FDA Label Image

Ndc 0591-4171-01 (Penicillamine Capsules 210976 3)

This is the description for Penicillamine Capsules USP 250 mg, a medication that comes in a child-resistant package and is usually taken by adults, according to the accompanying package outsert. The container should be kept closed and out of the reach of children. The medication is manufactured in India by Watson Pharma Private and is distributed by Tova Pharmaceuticals in North Wales, PA. However, there is some text missing from the , as there are several numbers and symbols that do not make sense when placed together.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.